Literature DB >> 19121475

Assessment of body protein: energy status in chronic kidney disease.

Noël J M Cano1, Magalie Miolane-Debouit, Julie Léger, Anne-Elizabeth Heng.   

Abstract

The prevalence of protein-energy malnutrition progressively increases during the evolution of chronic kidney disease (CKD). As a consequence, it has been reported that 40% of patients present with symptoms of undernutrition at the entrance to chronic dialysis treatment. In patients established on maintenance hemodialysis, the prevalence of malnutrition varies from 20% to 60% according to which indicators of nutritional status are used. Protein-energy malnutrition is associated with an increase in overall and cardiovascular death risks both in CKD patients not yet on dialysis and in dialysis patients. Given the impact of protein-energy wasting on the outcome of CKD patients, screening malnutrition and monitoring protein-energy status appear of primary importance. Therefore, scientific and professional societies or foundations have developed guidelines for the assessment of nutritional status as well as for the treatment of malnourished CKD patients. Recently, an expert panel recommended the term protein-energy wasting for loss of body protein mass and fuel reserves. According to these recommendations, protein-energy wasting should be diagnosed if 3 characteristics are present (low serum levels of albumin, transthyretin, or cholesterol), reduced body mass (low or reduced body mass or fat mass or weight loss with reduced intake of protein and energy), and reduced muscle mass (muscle wasting or sarcopenia, reduced mid-arm-muscle circumference). The present article addresses the methods for assessing protein-energy status, their specificities regarding the CKD staging, and the criteria for choosing among these methods when managing the follow-up evaluation of CKD patients. The practical implications of nutritional parameters for the management of CKD patients are illustrated by a case presentation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19121475     DOI: 10.1016/j.semnephrol.2008.10.008

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  6 in total

Review 1.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

2.  The prevalence of chronic kidney disease in the general population in Romania: a study on 60,000 persons.

Authors:  Vasile Cepoi; Mihai Onofriescu; Liviu Segall; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2011-03-02       Impact factor: 2.370

Review 3.  Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations.

Authors:  Oluwatoyin Bamgbola
Journal:  Pediatr Nephrol       Date:  2011-03-20       Impact factor: 3.714

4.  Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients.

Authors:  Nazanin Noori; Joel D Kopple; Csaba P Kovesdy; Usama Feroze; John J Sim; Sameer B Murali; Amanda Luna; Myra Gomez; Claudia Luna; Rachelle Bross; Allen R Nissenson; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-14       Impact factor: 8.237

5.  Potential Role of Nutrient Intake and Malnutrition as Predictors of Uremic Oxidative Toxicity in Patients with End-Stage Renal Disease.

Authors:  Robson E Silva; Ana C Simões-E-Silva; Aline S Miranda; Patrícia B I Justino; Maísa R P L Brigagão; Gabriel O I Moraes; Reggiani V Gonçalves; Rômulo D Novaes
Journal:  Oxid Med Cell Longev       Date:  2019-11-29       Impact factor: 6.543

6.  Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients.

Authors:  Julien Aniort; Marine Freist; Aurélien Piraud; Carole Philipponnet; Mohamed Hadj Abdelkader; Cyril Garrouste; Elodie Gentes; Bruno Pereira; Anne-Elisabeth Heng
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.